What is InClin?
InClin operates as a comprehensive Contract Research Organization (CRO), offering strategic consulting, clinical operations, biometrics, and medical writing services. The company partners with pharmaceutical and biotechnology firms to facilitate clinical trials across all phases, from Phase 1 through Phase 4. With a global presence spanning San Mateo, California, and Sydney, Australia, InClin is committed to advancing the development of innovative therapies aimed at improving patient quality of life. Its experienced team specializes in robust clinical trial management, delivering tailored solutions to meet diverse client needs.
How much funding has InClin raised?
InClin has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in InClin
PPP
Public-Private Partnership
What's next for InClin?
The recent major strategic investment signals a period of accelerated growth and expansion for InClin. This capital infusion is expected to bolster its service offerings, potentially enabling deeper penetration into key therapeutic areas and enhancing its capabilities in clinical trial execution. The company's focus on supporting drug development sponsors positions it to capitalize on the ongoing demand for efficient and high-quality CRO services in the competitive pharmaceutical and biotechnology landscape.
See full InClin company page
